Regenerative and New Allopathic Medicine for Hair Loss

ISHRS 2024 CME Webinar

Regenerative and New Allopathic Medicine for Hair Loss

Held Wednesday, May 15, 2024
Duration: 2 hours
Available on Demand

Registration Fees Per Webinar

A portion of the webinar was removed due to mitigation of conflicts of interest per CME policy.

Moderators

Moderator: Chiara Insalaco, MD, PhD | Italy
Co-Moderator: Guillermo Guerrero-Gonzalez, MD | Mexico

Program Description

The live online webinar will occur on the date and time as noted. The live program will be recorded and available for viewing on demand until January 10, 2025. This 2-hour CME activity is a live webinar which will be recorded with the intention to be re-watched or viewed as on-demand education. This webinar is being conducted to provide physicians with scientific updates and current studies related to medical management for patients with different types of hair loss using growth factors, peptides, mesotherapy, new molecules, autologous mesenchymal stem cells, SVF, PRP and others. As a result of this activity, learners will be able to gain more knowledge in current practices to manage the wide range of hair-loss conditions.

The online live component will include presentations, panel discussion, and audience participation via verbal questions and discussion, typing chat Q&A and polling.

Professional Practice Gap

More and more treatment modalities continue to appear. While regenerative medicine sounds promising, many therapies lack appropriate scientific backup to justify its use. The crucial aspect here is to understand the scientific basis of each treatment type to try to find the best type of scenario in which it could be used. Bridging this practice gap ensures physicians align with current studies, refining methodologies to make informed decisions on when to recommend or defer any of these therapies.

Educational Need

New therapies in regenerative medicine appear every year, all promising good results in patients with hair loss. It is of utmost importance that physicians are aware of new treatments, their foundations and possible applications. Not all therapies may be useful in a given patient, depending on their diagnosis. Doctors must take into account the cost-benefit ratio since some therapies may have a high cost. Finally, the principle of not harming the patient must always be remembered.

Learning Objectives

After this webinar, the attendees should be able to:

• Describe some of the regenerative medicine therapies and new molecules that have arisen in the last few years.
• Give examples on how each treatment modality may benefit a patient depending on the diagnosis.
• Recognize patients that may benefit from regenerative medicine, either as monotherapy or in combination with other medical or surgical treatments.
• Explain the limitations that these therapies may have.

Target Audience and Prerequisites

This webinar is taught at the physician level. It is open to all levels and geared toward advanced hair restoration surgeons

References

1. Kamali-Dolat Abadi M, Yousefi G, Dehghani F, Alizadeh AA, Jangholi A, Moadab MA, Naseh M, Parsa S, Nasiri G, Azarpira N, Dianatpour M. The Effect of Mesenchymal Stem Cells Derived-Conditioned Media in Combination with Oral Anti-Androgenic Drugs on Male Pattern Baldness: An Animal Study. Cell J. 2023 Nov 1;25(11):790-800. doi: 10.22074/cellj.2023.2008138.1377. PMID: 38071411; PMCID: PMC10711289.Bhatti HA, Basra MK, Patel GK. Hair restoration approaches for early onset male androgenetic alopecia. [Review]. J Cosmet Dermatol.2013; 12(3):223-231
2. Shimizu Y, Ntege EH, Sunami H, Inoue Y. Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. Regen Ther. 2022 Oct 31;21:527-539. doi: 10.1016/j.reth.2022.10.005. PMID: 36382136; PMCID: PMC9637724.
3. Anudeep TC, Jeyaraman M, Muthu S, Rajendran RL, Gangadaran P, Mishra PC, Sharma S, Jha SK, Ahn BC. Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia. Pharmaceutics. 2022 Mar 10;14(3):612. doi: 10.3390/pharmaceutics14030612. PMID: 35335987; PMCID: PMC8953616.
4. Gentile P, Garcovich S. Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. Int J Mol Sci. 2020 Apr 13;21(8):2702. doi: 10.3390/ijms21082702. PMID: 32295047; PMCID: PMC7216252.
5. Ruthvik S, John RS, George M, Kumar SP, Krishnan M. Comparison of Efficacy of Platelet-Rich Plasma With and Without Topical Minoxidil for Hair Growth in Patients With Androgenetic Alopecia: A Prospective Study. Cureus. 2024 Feb 8;16(2):e53875. doi: 10.7759/cureus.53875. PMID: 38465061; PMCID: PMC10924654.

CME Information

Continuing Medical Education (CME) Credit Statement

The International Society of Hair Restoration Surgery is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Society of Hair Restoration Surgery designates this Other Activity (blended synchronous and enduring) for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive CME credit and a CME certificate, participants must participate in the activity, complete the evaluation survey and the CME Claim Form by January 10, 2025.

Format

Internet/online, via computer or mobile device. 

Official Language

The official language of the webinar is English. Simultaneous interpretation is not provided for this webinar.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the ISHRS must ensure that anyone in a position to control the content of the educational activity (planners/ speakers/authors/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

• Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
• Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.  ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
• Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ISHRS manage any reported conflict and eliminate the potential for bias during the educational activity.  Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Disclosures of Relevant Financial Relationships of Planners, Faculty, and Others

The following individuals have no relevant financial relationships with ineligible companies to disclose:

Planners

Conradin von Albertini, MD, FISHRS – Planner
Waris Anwar, MBBS, FISHRS – Planner
Marco Barusco, MD, FISHRS – Planner
Victoria Ceh, MPA – Planner & Manager
Bruno F. Ferreira, MD – Planner
Guillermo Guerrero-Gonzalez, MD – Planner & Moderator
James A. Harris, MD, FISHRS – Planner
Chiara Insalaco, MD, PhD – Planner & Moderator
Rana Irfan, MBBS, FISHRS – Planner
Emily Middag – Planner and Manager
Ratchathorn Panchaprateep, MD, PhD, FISHRS – Planner
Marie A. Schambach, MD, FISHRS – Planner
Melanie Stancampiano – Planner & Manager

Faculty

Alba Gomez, MD | Spain
Oscar Muñoz, MD | Spain
Luis Sanchez, MD | Mexico
Robin Unger, MD | USA
Ryan Welter, MD, PhD | USA

The following individuals have relevant financial relationships:

Planners

None

Faculty

Sanusi H. Umar, MD, FISHRS | USA – FineTouch Laboratories Inc.: Ownership Interest

All of the relevant financial relationships listed for these individuals have been mitigated.

Commercial Support

None

Off-Label Or Other Non-FDA Approved, Investigational Use

Oscar Muñoz, MD – Botulinum Toxin in the Treatment of Alopecia
Botulinum Toxin

Sanusi H. Umar, MD, FISHRS – Use of a Novel Phytoactive Botanical Treatment
Topical Gashee (FineTouch Laboratories Inc); Oral Gashee (FineTouch Laboratories Inc); Tacrolimus; Pimecrolimus; Dutasteride; Minocycline

Other CME Information

Click for Continuing Medical Education Mission Statement
Learner Bill of Rights
ISHRS Privacy and Confidentiality Policy for Internet CME

Disclaimer

The webinar content has been made available by the ISHRS for educational purposes only. The content is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather is intended to present views, statements, and opinions that may be of interest to others. The views expressed herein are those of the individual authors and not necessarily those of the ISHRS. The ISHRS assumes no responsibility or liability in connection with your use or misuse of the webinar content or any materials or techniques described in the content, and it makes no warranty or representation as to the validity or sufficiency of any information provided.

Questions: Learners may contact the ISHRS Headquarters with questions about this CME activity at phone +1-800-444-2737 or +1-630-262-5399, or fax +1-630-262-1520, or email: gro.srhsiobfsctd-6766a2@ofni